2) They are just seeking for a protocol modifications. We are 3 years from the data readout, then a year or longer to an approval. Interim read out could help, but that timeline is a killer. The company will not survive until then. "The company is in discussions with the FDA to allow for an earlier interim analysis for efficacy under proposed revisions to the AIM2CERV protocol."